Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
100%
Inflammatory Arthritis
100%
Janus Kinase Inhibitor
41%
Upadacitinib
27%
Baricitinib
27%
Tofacitinib
27%
Methotrexate
27%
Adverse Event
26%
Disease Activity
20%
Filgotinib
15%
Heart Bundle Branch Block
12%
Prevalence
12%
Immune Checkpoint Inhibitor
12%
Leflunomide
12%
Tocilizumab
12%
Spondylarthritis
12%
Atrioventricular Block
12%
Gout
12%
Anakinra
12%
Giant Cell Arteritis
12%
Biological Product
11%
Combination Therapy
9%
Remission
7%
Arthritis
6%
Monotherapy
6%
Randomized Clinical Trial
6%
Psoriatic Arthritis
5%
Non Insulin Dependent Diabetes Mellitus
5%
Immunology and Microbiology
Inflammatory Arthritis
86%
Platelet
36%
Tumor Necrosis Factor
25%
Prevalence
18%
Positron Emission Tomography-Computed Tomography
18%
Systemic Lupus Erythematosus
17%
Interleukin 6
17%
Rheumatic Polymyalgia
15%
B Cell
13%
Patient Coding
12%
Lymphocyte
12%
FCGR2A
12%
Transcriptomics
12%
Giant Cell Arteritis
12%
Immunity
12%
Gout
12%
X-Ray Computed Tomography
10%
CD14
7%
Adalimumab
6%
Methotrexate
6%
Medline
5%
Infliximab
5%
Keyphrases
Rheumatoid Arthritis
14%
Baricitinib
14%
Tofacitinib
14%
Rheumatoid Arthritis Patients
13%
Janus Kinase Inhibitors
12%
Sjgren's Syndrome
12%
Clinical Features
12%
Phenotypic Outcome
12%
CD39 and CD73 Expression
12%
Monocytes
12%
Clinically Significant
12%
Sex-related Differences
12%
Novel Autoantibodies
12%
Long-standing Disease
12%
Deep Gluteal Space
12%
Hip Rotation
12%
B Cell Abnormalities
12%
Type 2 Diabetic Patients
12%
Functional Consequences
12%
Platelets
12%
Autoantibodies
12%
Treatment Efficacy
9%
Persistent Arthritis
9%
Inhibitor Treatment
8%
Low Disease Activity
8%
Remission
8%
Disease Activity Score 28 (DAS28)
7%
Rheumatic Immune-related Adverse Events
6%
DMARD Therapy
6%
Immune Checkpoint Inhibitor Therapy
6%